

		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
		Applicants: Li-Huei Tsai et al. 1632						
		Filing Date: July 24, 2003					Group: 1614	
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
MS	AA	4,736,866	04/12/98	Leder et al.	800	1	06/22/84	
MS	AB	4,816,567	03/28/89	Cabilly et al.	530	387	04/08/83	
MS	AC	4,870,009	09/26/89	Evans et al.	435	70	12/15/83	
MS	AD	4,873,191	10/10/89	Wagner et al.	435	172.3	08/18/86	
MS	AE	4,873,316	10/10/89	Meade et al.	530	412	01/23/87	
MS	AF	5,223,409	06/29/93	Ladner et al.	435	69.7	03/01/91	
MS	AG	5,225,539	07/06/93	Winter	530	387.3	10/25/91	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
MS	AH	EP 0 125 023	11/14/84	Europe				
MS	AI	EP 0 171 496	02/19/86	Europe				
MS	AJ	EP 0 173 494	03/05/86	Europe				
MS	AK	EP 0 184 187	06/11/86	Europe				
MS	AL	EP 0 264 166	04/20/88	Europe				
MS	AM	WO 86/01533	05/07/87	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MS	AN	Ahlijanian et al., "Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5," <i>Proc. Natl. Acad. Sci.</i> , 97:2910-2915 (2000)						
MS	AO	Bibb et al., "Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons," <i>Nature</i> , 402:669-671 (1999)						
MS	AP	Bibb et al., "Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5," <i>Nature</i> , 10:376-380 (2001)						
MS	AQ	Delalle et al., "Temporal and spatial patterns of expression of p35, a regulatory subunit of cyclin-dependent kinase 5, in the nervous system of the mouse," <i>J. Neurocytol.</i> , 26:283-296 (1997)						
MS	AR	De Strooper and Annaert, "Proteolytic processing and cell biological functions of the amyloid precursor protein," <i>J. Cell Sci.</i> , 113:1857-1870 (2000)						
EXAMINER /Magdalene Sgagias/				05/19/2006		DATE CONSIDERED		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
INFORMATION DISCLOSURE CITATION Sheet 2 of 4				Applicants: Li-Huei Tsai et al.		1632		
				Filing Date: July 24, 2003		Group: 1614		
U.S. PATENT DOCUMENTS								
Examiner Initial	BA	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
MS	BB	WO 87/02671	03/13/86	PCT				
	BC	WO 90/02809	03/22/90	PCT				
	BD	WO 91/17271	11/14/91	PCT				
	BE	WO 92/01047	01/23/92	PCT				
	BF	WO 92/09690	06/11/92	PCT				
	BG	WO 92/15679	09/17/92	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MS	BH	Dhavan and Tsai, "A Decade of Cdk5," <i>Nat. Rev. Mol. Cell Biol.</i> , 2:749-759 (2001)						
	BI	Fischer et al., "Cyclin Dependent Kinase 5 Is Required for Associative Learning," <i>J. Neurosci.</i> , 22(9):3700-3707 (2002)						
	BJ	Grynspan et al., "Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease," <i>Brain Res.</i> , 763:145-158 (1997)						
	BK	Gupta et al., "Life Is a Journey: . . .," <i>Nat. Rev. Genet.</i> , 3:342-357 (2002)						
	BL	Hsiao et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274:99-102 (1996)						
	BM	Keshvara et al., "Cyclin-Dependent Kinase 5 Phosphorylates Disabled 1 Independently of Reelin Signaling," <i>J. Neurosci.</i> , 22:4869-4877 (2002)						
	BN	Khachaturian, "Diagnosis of Alzheimer's Disease," <i>Arch. Neuro.</i> , 42:1097-1105 (1985)						
	BO	Kusakawa et al., "Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25," <i>J. Biol. Chem.</i> 275:17166 (1999)						
	BP	Ledda et al., "Target-Derived GFR α 1 as an Attractive Guidance Signal for Developing Sensory and Sympathetic Axons via Activation of Cdk5," <i>Neuron.</i> , 36:387-401 (2002)						
	BQ	Lewis et al., "Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein," <i>Nat. Genet.</i> , 25:402-405 (2000)						
EXAMINER		/Magdalene Sgagias/			05/19/2006		DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.								

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
INFORMATION DISCLOSURE CITATION Sheet 3 of 4				Applicants: Li-Huei Tsai et al.				1632
				Filing Date: July 24, 2003				Group: 4614
U.S. PATENT DOCUMENTS								
Examiner Initial	CA	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES NO	
MS	CB	WO 92/18619	10/29/92	PCT				
	CC	WO 92/20791	11/26/92	PCT				
	CD	WO 93/01288	01/21/93	PCT			X	
	CE	WO 00/36093	06/22/00	PCT				
	CF	WO 01/57183	08/09/01	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MS	CG	Lewis et al., "Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP," <i>Science</i> , 293:1487-1491 (2001)						
	CH	Li et al., "Regulation of NMDA receptors by cyclin-dependent kinase-5," <i>Proc. Natl. Acad. Sci. USA</i> , 98(22):12742-12747 (2001)						
	CI	Mattson, "Cellular Actions of β -Amyloid Precursor Protein and its Soluble and Fibrillogenic Derivatives," <i>Physiol. Rev.</i> , 77:1081-1132 (1997)						
	CJ	Mayford et al., "Control of Memory Formation through Regulated Expression of a CaMKII Transgene," <i>Science</i> , 274:1678-1683 (1996)						
	CK	Niethammer et al., "NUDEL Is a Novel Cdk5 Substrate that Associates with LIS1 and Cytoplasmic Dynein," <i>Neuron</i> , 28:697-711 (2000)						
	CL	Nikoloic et al., "The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation," <i>Genes Dev.</i> , 10:816-825 (1996)						
	CM	Patrick et al., "Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration," <i>Nature</i> , 402:615-622 (1999)						
	CN	Price et al., "Amyloid beta amyloidosis in Alzheimer's disease," <i>Curr. Op. Neurol.</i> , 8:268-274 (1995)						
	CO	Ramelot et al., "Phosphorylation-induced Structural Changes in the Amyloid Precursor Protein Cytoplasmic Tail Detected by NMR," <i>J. Mol. Biol.</i> , 307:871-884 (2001)						
	CP	Sasaki et al., "A LIS1/NUDEL/Cytoplasmic Dynein Heavy Chain Complex in the Developing and Adult Nervous System," <i>Neuron</i> , 28:681-696 (2000)						
	CQ	Sasaki et al., "Fyn and Cdk5 Mediate Semaphorin-3A Signaling, which Is Involved in REgulation of Dendrite Orientation in Cerebral Cortex," <i>Neuron</i> , 35:907-920 (2002)						
EXAMINER				/Magdalene Sgagias/		05/19/2006		
DATE CONSIDERED								
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

USPTO Form 1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00054		Serial No. 10/625,986		
INFORMATION DISCLOSURE CITATION Sheet 4 of 4				Applicants: Li-Huei Tsai et al.		1632		
				Filing Date: July 24, 2003		Group: 1614		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	DA							
	DB							
	DC							
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	DD							
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MS	DE	Selkoe, "Transplanting cell biology into therapeutic advances in Alzheimer's disease," <i>Nature</i> , 399[Supp]:A23-A31 (1999)						
	DF	Suri et al., "Catecholeminergic Cell Lines from the Brain and Adrenal Glands of Tyrosine Hydroxylase-SV40 T Antigen Transgenic Mice," <i>J. Neurosci.</i> , 13(3):1280-1291 (1993)						
	DG	Tang et al., "An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator," <i>J. Biol. Chem.</i> 270(45):26897-26903 (1995)						
	DH	Taniguchi et al., "Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains," <i>FEBS Lett.</i> 489:46-50 (2001)						
	DI	Tomizawa et al., "Localization and Developmental Changes in the Neuron-Specific Cyclin-Dependent Kinase 5 Activator (p35 ^{nck5a}) in the Rat Brain," <i>Neurosci.</i> , 74(2):519-529 (1996)						
	DJ	Tsai et al., "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5," <i>Nature</i> 371:419-423 (1994)						
	DK	Tseng et al., "A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains," <i>FEBS Lett.</i> 523:58-62 (2002)						
	DL	Yang and Hinds, "Increased Ezrin Expression and Activation by CDK5 Coincident with Acquisition of the Senescent Phenotype," <i>Mol. Cell</i> , 11:1163-1176 (2003)						
	DM	Yankner, "Mechanisms of Neuronal Degeneration in Alzheimer's Disease," <i>Neuron</i> , 16:921-932 (1996)						
	DN	Yoo and Lubec, "p25 protein in neurodegeneration," <i>Nature</i> , 411:763-764 (2001)						
	DO	Younkin, "Evidence that Aβ42 Is the Real Culprit in Alzheimer's Disease," <i>Ann. Neurol.</i> 37:287-288 (1995)						
↓	DP	English abstract of WO 93/01288						
EXAMINER /Magdalene Sgagias/				05/19/2006		DQ		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

INFORMATION DISCLOSURE CITATION

Sheet 1 of 1

Applicants: Li-Huei Tsai et al.

1632

Filing Date: July 24, 2003

Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
AA						
AB						
AC						
AD						
AE						
AF						
AG						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
AH								
AI								
AJ								
AK								
AL								
AM								

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

MS	AN	Cruz et al., "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles," <i>Neuron</i> , 40(3):471-483 (2003)
MS	AO	Wang et al., "Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors," <i>Nat. Neurosci.</i> , 6(10):1039-1047 (2003)
MS	AP	Zhang et al., "Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice," <i>Am J Pathol.</i> , 165(3):843-853 (2004)
	AQ	
	AR	

EXAMINER

/Magdalene Sgagias/

05/19/2006

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.